Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Procter & Gamble Co. will be the first company with a drug on the market to treat sexual dysfunction in women. The testosterone skin patch, to be called Intrinsa, significantly improved sexual desire and satisfaction in women whose ovaries had previously been removed, according to data presented at the Endocrine Society of America annual meeting in New Orleans.
Armed with data from two large phase III clinical trials that appear to demonstrate safety and efficacy of Intrinsa, P&G believes it now has the information needed to seek approval from U.S. regulators.
Although the company declined to discuss when it would file its new drug application with the Food and Drug Administration, P&G spokeswoman Mary Johnson said if approved they hope to have Intrinsa available by prescription sometime next year.
The drug would be prescribed to increase sexual desire in menopausal women who have experienced loss of desire and are distressed by that loss.
"This is huge," said Sheryl Kingsberg, an associate professor of reproductive biology at Case Western Reserve University and one of the lead investigators of the trial. "It’s important to get it out there because we don’t have any approved medical treatment on the market for female sexual dysfunction that clinicians can look at as safe and effective," Kingsberg said.
In P&G’s latest 24-week trial involving 533 women, patients taking Intrinsa reported a 51 percent increase in frequency of "satisfying sexual activity" and a 49 percent increase in sexual desire, compared with their previous experience.
In a similar study of 562 women released in May, women receiving the patch had a 74 percent increase in frequency of satisfying sexual activity and a 56 percent increase in sexual desire.
P&G said it is currently conducting two more late-stage clinical studies of the testosterone patch in menopausal women who have not had surgery to remove their ovaries, Johnson said.
Analysts have said drugs for female sexual dysfunction that prove effective in treating problems with desire, arousal or ability to achieve orgasm could garner sales in excess of $1 billion a year. The Endocrine Society 86th Annual Meeting. ENDO 2004: The Endocrine Society 86th Annual Meeting
Learn about the First Step Program, a program to increase physical activity, that has gone through 8 years of clinical studies to show it’s effectiveness. www.firststepprogram.com
===========================
|
|
Dr. Richard Bernstein’s book the Diabetes Solution NEW AND REVISED